Aeson, Research Corp. Technologies, Temple University deal

Research Corp. Technologies (RCT) formed Aeson Therapeutics to develop fluasterone, a synthetic version of dehydrepi-androsterone (DHEA), to prevent breast cancer, and as a treatment for lupus erythematosus and Type II diabetes.

Aeson, which will receive an undisclosed amount of funding, hopes to enter clinical studies by the end of next year. ...